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In the last decade, we have witnessed substantial progress in our understanding of corneal biomechanics and architecture. It is well
known that diabetes is a systemic metabolic disease that causes chronic progressive damage in themain organs of the human body,
including the eyeball. Although the main and most widely recognized ocular effect of diabetes is on the retina, the structure of the
cornea (the outermost and transparent tissue of the eye) can also be affected by the poor glycemic control characterizing diabetes.
The different corneal structures (epithelium, stroma, and endothelium) are affected by specific complications of diabetes. The
development of new noninvasive diagnostic technologies has provided a better understanding of corneal tissue modifications.The
objective of this review is to describe the advances in the knowledge of the corneal alterations that diabetes can induce.
1. Introduction
The first World Health Organization (WHO) global report
on diabetes mellitus indicates that the number of adults
living with this disorder has almost quadrupled since 1980 to
422 million adults. This large increase is due mainly to a
higher incidence of type 2 diabetes (T2D) and the influence
of factors such as overweight and obesity [1]. Diabetes is a
systemic metabolic disease associated with high morbidity
and mortality that can affect almost all tissues of the human
body, including the most superficial and transparent ocular
tissue: the cornea [2–7]. The prolonged high blood glucose
levels that occur in diabetes can cause severe ophthalmo-
logical complications that affect both the anterior and
posterior segments of the eye and can produce a significant
visual deficit, including blindness. The eyeball is an organ
accessible to noninvasive exploration and can provide great
information about the possible involvement of other sys-
temic organs caused by diabetes. The different corneal
components (epithelium, stroma, nerves, and endothelium)
are each affected by specific complications related to diabetes
and poor glycemic control. It is well known that diabetic
retinopathy is a good indicator of the state of microvascular
disease in the rest of the organs. In the same way, the changes
in corneal structures that we can recognize with new
noninvasive technologies could predict systemic complica-
tions of diabetes or evaluate control of the disease. These
changes in the corneal nerves of patients with diabetes could
predict systemic conditions such as peripheral and auto-
nomic neuropathy, while the state of the endothelial cells or
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changes in corneal thickness could inform on the status and
level of control of the disease.The possibility of identification
of structural and biomechanical changes of the cornea in
patients with diabetes by means of accessible and non-
invasive techniques can offer a new possibility for the early
treatment of possible systemic complications. An improved
knowledge of the changes produced by diabetes in the
cornea and advances in diagnostic technology made in the
last 10 years have led to substantial progress in our un-
derstanding of the biomechanics and architecture of the
cornea.This review summarizes advances in our knowledge
of the clinical manifestations and the “layer by layer” corneal
changes that diabetes can produce.
2. Materials and Methods
We have carried out a systematic review of the literature
published between January 1, 2008 and November 1, 2018
concerning the role of diabetes in structural and bio-
mechanical changes in the cornea. A literature search was
conducted in the NCBI Entrez PubMed database combining
the term “diabetes” with a series of key words such as
“corneal epithelium,” “corneal thickness,” “corneal stroma,”
“corneal biomechanics,” “ocular response analyzer,” “cor-
neal hysteresis,” “corneal nerves,” and “corneal endothe-
lium.” Of the 314 manuscripts registered initially, those that
were duplicated or without a summary in English were
excluded, and 243 articles were finally examined by the
coauthors to determine their relevance. The articles that
included only the posterior segment were considered not
relevant. A total of 81 papers were deemed irrelevant.
3. Diabetes and the Corneal Epithelium
Diabetes is associated with ocular surface disorders such as
dry eye, superficial punctate keratitis, recurrent corneal
erosion syndrome, and persistent epithelial defects [8, 9].
The underlying and responsible mechanisms that have been
suggested for the appearance of these pathologies are a loss
of corneal innervation (see Corneal Nerves in Diabetes), loss
of basal epithelial cells, production and accumulation of
advanced glycation end products (AGEs), disruption of tight
junctions between epithelial cells, and disruption of trophic
factors that encourage wound healing.
3.1. Basal Epithelial Cell Density (BECD). Cai et al. [10]
evaluated the effects of type 1 diabetes (T1D) on the whole
cornea, corneal sublayer thickness, and basal epithelial cell
density (BECD) using in vivo corneal confocal microscopy
(CCM) in a streptozotocin-induced diabetic mouse model.
They found reduced BECD and a decreased thickness of the
corneal epithelium in these diabetic mice. Dehghani et al.
[11] reported a decrease in the thickness of basal and in-
termediate epithelial cell density in a human in vivo case-
control study with laser-scanning CCM in a cohort of di-
abetic patients. Similar results were obtained by Szalai et al.
[12] and Qu et al. [13], who also found a significant decrease
in the cell population of the basal epithelial layer. Different
mechanisms have been proposed as causal for this outcome,
including decreased innervation at the subbasal nerve plexus
(SBNP) (see Corneal Nerves in Diabetes), increased base-
ment membrane thickness, or metabolic dysfunctions as-
sociated with the accumulation of AGEs in the basal
membrane [11, 14].
3.2. Epithelial BasementMembrane. Classically, diabetes has
been associated with corneal epithelial basement membrane
(BM) disorders [15–17]. BM becomes irregularly thickened
and multilaminated, with abnormal adhesions to the
supralying epithelium [18], and has been related to accu-
mulation of AGEs.This enlarged configuration of the basal
membrane leads to subclinical scattering of light in the
cornea visible on in vivo CCM, but not detectable on routine
clinical examination [19, 20]. Recently, O¨zyol and O¨zyol
[21], by using Scheimpflug tomography in a cohort of di-
abetic patients scanned by densitometry, detected that the
anterior corneal layer displayed significantly higher values
on light scattering in diabetic eyes than in the eyes of
controls.
Regarding the biochemical changes in the composition
of the corneal BM, Ljubimov et al. [17, 22] reported a
markedly diminished change with a weak staining for chains
of laminin-l, entactin/nidogen, laminin-10, and a3-a4 chains
of type IV collagen in diabetic corneas with diabetic reti-
nopathy. Saghizadeh et al. [23] also found reduced immu-
nostaining of laminins, entactin/nidogen-1, and laminin
receptor integrin α3β1. In addition, they report a significant
decrease in the laminin c3 chain and fibronectin [24].
Different hypotheses could be responsible for these changes
in the composition of the corneal BM, an increase in the
activity of the proteinases, and a decrease of growth factors
or diffusion from the vitreous or the retina of pathological
substances associated with hyperglycemia may vary the
composition of the corneal BM. Moreover, it has been
suggested that changes in the composition of the corneal BM
in diabetic patients could alter the interaction between
epithelial cells and the underlying basal membrane, trig-
gering variations in the expression patterns of integrins [25].
3.3. Tight Junctions. The major function of the corneal
epithelium is to protect the interior of the eye; the corneal
epithelium creates “tight junctions”—physical and chemical
barriers that protect against infection, maintaining corneal
transparency and integrity. Epithelial cell junctions, visu-
alized as electron dense structures, play an important role in
the formation and maintenance of the epithelial barrier,
homeostasis, and host defense of the cornea.
Huang et al. [26], using a diabetes rat model, found
delayed corneal healing with fewer multilayers of epithelium
covering the denuded surface at 48–72 hours, with increased
disorganization of occludin protein stained with immuno-
fluorescence. Scanning electron microscopy revealed ab-
normal intercellular connections, fissures between cells, a
decrease in the number of microvilli, and dropsy in the
diabetic rat group. Yin et al. [27] reinforced this idea when
they observed a delayed, but not absent, formation of tight
junctions between cells during the healing process of
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epithelial corneal ulcers in diabetic rats.There are no studies
in humans that corroborate these findings in animal models.
3.4. Advanced Glycation End Products (AGEs). AGEs have
been proposed as the cause of the abnormalities seen in the
cornea of patients with diabetes. They are a heterogeneous
group of substances that result from the nonenzymatic
glycation and oxidation of proteins and lipids. AGEs
stimulate cell apoptosis by increasing intracellular reactive
oxygen species (ROS) production [28, 29].
The accumulation of AGEs leads to alterations in tissue
function. AGE accumulation has been detected at the site of
the corneal epithelium and epithelial BM in diabetic rats [30,
31] and monkeys [32] and in human diabetes patients [29].
In addition, it has been shown that the AGE concentration is
elevated in the tears of human diabetes patients [33]. Kim
et al. [30] demonstrated both the accumulation of AGEs and
the presence of oxidative DNA damage in diabetic corneal
cells. They found a correlation between the apoptotic
damage in the diabetic cornea and the intense nuclear
localization of a marker of oxidative DNA damage
(8-hydroxydeoxyguanosine). These findings provide strong
evidence that nuclear oxidative DNA damage by AGE ac-
cumulation is responsible, at least in part, for the apoptotic
damage of diabetic corneal cells, leading to delayed epithelial
wound healing in the diabetic cornea.
3.5. Wound Healing. Several authors have recently dem-
onstrated delayed wound healing in diabetic rat models [27,
34, 35]. Longer healing times than those in the control group
were observed in a group of diabetic rats in which a me-
chanical debridement had been performed. Growth factors
and cytokines are powerful regulators of cell behavior and
promote tissue wound healing. Disruption of trophic factors
has been identified as being responsible for delayed corneal
healing in both human and animal models of diabetes. An
important example is epidermal growth factor receptor
(EGFR); this pathway is critical for cell migration and
proliferation and is a major mediator of corneal epithelial
wound healing [36]. Several authors have reported dis-
ruption of this pathway in the cornea of diabetic rats [27]
and in human corneal epithelial cells [37, 38].
Another altered pathway is mediated by hepatocyte
growth factor (HGF) which is involved in the processes of
cellular proliferation, migration, and apoptosis [24, 39]The
HCG receptor, the proto-oncogene c-Met, is apparently
involved in activation of p38 mitogen-activated protein
kinase (p38 MAPK) which has been related to stimulation of
corneal epithelial migration [40]. Saghizadeh et al. reported
an increased expression of HGF and a diminished c-Met
expression in the diabetic cornea [41]. Recent studies carried
out by the same group of researchers have developed an
adenoviral-based gene therapy in human diabetic cultured
corneas, improving wound healing times by normalizing the
levels of c-Met expression, associated or not with the nor-
malization of other proteinases or kinases whose values are
usually altered in the corneas of diabetic patients [24, 41–44].
Other routes which have recently been studied include
Serpine 1 [35], which, when compared to controls, is sig-
nificantly diminished in corneal epithelium collected from
diabetic rats. In addition, opioid growth factor (OGF) [45,
46], which is elevated in the plasma of patients with diabetes,
acts as a negative regulator of epithelial proliferation and
wound healing. When OGF joins to its specific receptor,
OGFr, they are able to inhibit cell replication [46]. Moreover,
it has been observed that opioids antagonists such as nal-
trexone, which block the axis OGF-OGFr, favor cell repli-
cation and therefore tissue remodeling [45].
Likewise, insulin-like growth factor sun-1 (IGF-1) and its
receptor, which are found in human corneal keratocytes and
epithelial cells, mediate cell migration, proliferation, and
survival. It appears that elevated levels of insulin-like growth
factor binding protein 3 (IGFBP-3) found in the tears of
diabetic human subjects may attenuate IGF-1 receptor sig-
naling in the diabetic cornea [47]. According to Wang et al.
[48,49], this attenuation via IGFBP3/IGF-1 could be promoted
by Sirtuin 1 (silent mating type information regulation 2
homolog), a protein that belongs to the group of class III
histone/protein deacetylases. In addition, Shen et al. [50]
reported that corneal wounds in diabetes have abnormal
electric signals which may contribute to impaired wound
healing, possibly via cell electrotactic migration disruption,
and even suggest electrical stimulation as a new therapeutic
option in themanagement of chronic and nonhealingwounds.
4. Diabetes and Corneal Stroma
4.1. Corneal Nerves in Diabetes. The structure of the corneal
nerves is very important in maintaining a healthy ocular
surface.The cornea is the most densely innervated tissue in
the human body (approximately 7,000 nociceptors per mm2)
[51]. This great sensitivity serves to protect the cornea. The
corneal nerves are derived from the ciliary nerves that form
the terminal branches of the ophthalmic division of the 5th
cranial nerve. These bundles of nerves penetrate radially in
the middle and anterior corneal stroma through the limbus
and then bifurcate and advance towards the epithelium as
long bundles, fine branches, and nerve terminals [52]. This
results in a moderately dense midstromal plexus and a dense
subepithelial plexus, whose branches cross Bowman’s
membrane to form an SBNP complex that emits nerve
terminals that innervate all epithelial layers [53]. The dif-
ferent types of nerve endings (nociceptive, temperature, and
polymodal) are responsible for sensations such as pain,
touch, temperature, and dryness, which are very important
for the reflex of blinking, the production of tears, and the
healing of lesions [54–58].
Diabetes is a systemic condition that can affect corneal
innervation and sensitivity, causing complications that can
lead to blindness. Patients with diabetes show a reduction in
corneal sensitivity, clinically measured with an esthesi-
ometer [59], due to a progressive decrease in the density of
the corneal nerves [60]. Advances in technology have
allowed for rapid, noninvasive, and high-quality visualiza-
tion of the corneal structure using in vivo CCM.The corneas
of patients with diabetes show a lower density of SBNP, a
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reduction of epithelial nerve fiber bundles per image with
decreased branches, and greater nervous tortuosity than the
corneas of healthy patients [61, 62]. These alterations are
associated with a reduction in corneal sensitivity in patients
with diabetes [63]. He and Bazan studied the architecture of
corneas donated by patients with insulin-dependent diabetes
of varying duration. Although they did not find differences
in the number of nerve trunks of the stroma, they found a
decrease in the density of epithelial nerves in the corneas of
patients with 5 or more years’ duration of insulin-dependent
diabetes. The presence of abundant loops of nerve fibers in
the corneal stroma, which appeared to be formed as a result
of resistance in the BM to the penetration of the stromal
nerve branches in the epithelia, was also observed [64].
Damage to the corneal nerve fibers leads to an alteration
of the healing process of the wounds and greater suscep-
tibility to infections; this damage causes most of the
symptoms experienced by diabetes patients with keratop-
athy, such as decreased corneal sensitivity, recurrent corneal
erosions, persistent epithelial defects, and neurotrophic
corneal ulcers [65–67].
Examination of the corneal nerves and exploration of
corneal sensitivity are useful tools for the early detection and
evaluation of peripheral neuropathy in patients with di-
abetes. Several studies have shown that CCM is a valid,
accurate, noninvasive method to identify small nerve fiber
pathology; CCM can also be used to diagnose diabetic
neuropathy [68, 69]. It has been found that corneal nerve
fiber density and length, as well as corneal nerve branch
density, are significantly reduced in patients with diabetic
polyneuropathy when compared to control subjects. The
diagnostic efficiency of CCM is comparable to intra-
epidermal nerve fiber density by skin biopsy; however, CCM
may be preferred due to its rapid, automated, and non-
invasive characteristics [69]. What is important to recognize
is that CCM can identify nerve alterations in the cornea that
precede the clinical signs and symptoms of peripheral
neuropathy, nephropathy, or diabetic retinopathy. Asghar
et al. observed alterations even in patients with impaired
glucose tolerance but who did not meet the clinical criteria of
T2D [70]. CCM is also useful in the assessment of a patient’s
response to treatments, since it has been found that there is a
recovery of corneal SBNP and an improvement of neu-
ropathy in diabetes patients who have received a double
pancreas and kidney transplant [71, 72]. A recent study using
in vivo CCM has found that nerve fiber damage in T1D
correlates with the degree of diabetic retinopathy. Fur-
thermore, studies show that T1D patients with higher age at
diagnosis have a higher nerve fiber density. These results
indicate that age at T1D diagnosis potentially has an im-
portant effect on final nerve fiber density [73]. In conclusion,
studies show that CCM offers an early, faster, and less in-
vasive diagnosis of diabetic peripheral neuropathy than
current gold standard techniques such as nerve electro-
physiology, sural nerve biopsy, and skin puncture biopsy.
4.2. Corneal Stroma Structure and Biomechanics in Diabetes.
The stroma represents 90% of the corneal thickness; its
special structure and composition give the cornea its
biomechanical properties [74]. The highly differentiated
ultrastructure of the corneal stroma, with its special ori-
entation, diameter, and separation of fibrillar collagen
bundles and the regulatory role of other components of the
extracellular matrix (proteoglycans and glycosaminogly-
cans), confer transparency and biomechanical behavior to
the cornea [75, 76]. The way in which diabetes affects the
structure and function of the corneal stroma is not well
known; there have been numerous studies in recent years
into how diabetes affects corneal thickness and the bio-
mechanical properties of the corneal stroma. The main
points of interest in the reviewed papers on corneal bio-
mechanics in diabetes involved the in vivo measurement of
the corneal biomechanical properties; this was largely due to
the recent development of technological devices to quantify
some of these properties. The first of these was the Ocular
Response Analyzer (ORA, Reichert Ophthalmic In-
struments, Depew, NY, USA), and more recently the Corvis
ST (Corvis ST; Oculus, Wetzlar, Germany). In addition, in
the last two years, details of corneal optical densitometry
(COD) analysis using the Pentacam HR imaging system in
diabetes patients have been published.
4.2.1. Corneal Thickness. Recently published research find-
ings on corneal morphology show evidence of greater central
corneal thickness (CCT) in patients with T2D [77–80]. In
studies of corneal thickness in patients with diabetic reti-
nopathy, no statistical differences were found between groups
of patients with proliferative retinopathy or nonproliferative
retinopathy and those without diabetic retinopathy [81–85].
These results indicate that diabetes patients have a signifi-
cantly thicker CCT, regardless of the state of retinopathy.
Santiagu et al. [86] found that diabetes during pregnancy also
does not seem to influence CCT. In a recent article, Kumar
et al. [87] showed that CCTincreases in relation to the severity
of peripheral diabetic neuropathy due to an increase in
stromal thickness. Other studies, however, have not found an
increase in CCT in cases of T1D [88] or T2D patients [89–91].
Similarly, studies of patients with primary open-angle glau-
coma (POAG) did not show differences in CCT between
groups of glaucoma patients with and without diabetes [92,
93]. Hashemi et al. [94], in a five-year follow-up study,
showed that overall patterns of change in CCT and corneal
shape in diabetes patients over 40 years of age were similar to
those observed in those individuals without diabetes. How-
ever, changes related to age in the thickness, volume, and
shape of the central and peripheral cornea were less pro-
nounced in subjects with diabetes.
Several studies on corneal thickness and biomechanics
have been conducted in children with T1D. Tiutiuca [95]
conducted a study in 100 children with T1D in Romania that
showed an increase in CCTwhen compared to an equivalent
number of healthy children.These results are comparable to
those from a similar study conducted in Turkey by Akinci
et al. [96]. However, other studies have not found this in-
crease in CCTin children or young people with T1D [97, 98].
In another Turkish study in children with T1D, CCTwas not
shown to be associated with either the current fasting
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glucose level or duration of disease [99]. However, in a
recent clinical paper on corneal thickness in T1D, higher
CCT values were observed in acute hyperglycemia state,
when compared with those obtained after 48 hours of
metabolic compensation, concluding that corneal pachy-
metry can potentially serve as a promising method for
noninvasive evaluation of the increased risk of developing
cerebral edema in patients with T1D [100].
4.2.2. Biomechanical Properties. ORA and Corvis ST are
noncontact devices that provide tonometry and corneal dis-
placement measurements via the injection of a rapid jet of air.
ORA was the first device capable of evaluating in vivo bio-
mechanical properties such as corneal hysteresis (CH) and
corneal resistance factor (CRF), calculated from the differ-
ences in pressures that act to achieve defined corneal de-
formation states. In addition, ORA provides the intraocular
pressure (IOP) correlated with the Goldmann IOP (IOPg) and
the compensated corneal IOP (IOPcc). CH predominantly
reflects the viscous properties of corneal tissue, whereas CRF is
an empirically derived measurement representative of the
elastic properties of the cornea [101]. Both parameters are
derived from a complex interaction between the collagen
composition of the cornea, its thickness, hydration, age, and
other physiological factors [102, 103]. Studies have shown that
lower CH valuesmay be associated with several disorders such
as keratoconus, Fuchs endothelial corneal dystrophy, and
glaucoma [104–106].Themeasures provided by the ORA have
not been affected by CCT values [107].
Table 1 summarizes the publications in the last ten years
that concern biomechanical corneal properties measured
with ORA in diabetes patients. In most of the cross-sectional
studies reviewed, it has been found that subjects with di-
abetes have higher CH values than the population without
diabetes [74, 91, 92, 108, 110, 112, 115–118]. Only three
studies [109, 113, 114] reported that subjects with diabetes
have a lower CH when compared to age-matched controls,
and four others did not find significant differences in CH
values between populations with and without diabetes [99,
111, 115, 119]. A possible relationship between increased CH
and the control of diabetes has also been investigated.
Kotecha et al. [110] found that the level of glucose in the
blood correlated significantly (but weakly; r! 0.28) with
Hashemi et al. [94] found that subjects with fasting blood
glucose values greater than or equal to 7.0mM had higher
CH and CRF values than those with glucose values less than
6.1mM. Regarding corneal biomechanical properties in
diabetic children, two studies show that T1D does not have
any effect on corneal biomechanical parameters (CH and
CRF) in childhood [99, 111] (Table 1). We found only one
study that analyzed the results of these biomechanical pa-
rameters measured with Corvis ST in a diabetes population:
Perez-Rico et al. [113] found differences in some parameters
of corneal deformation in the diabetic population, with an
increase in the time of the first applanation and a significant
decrease in some parameters, such as the time of second
applanation, the velocity of the first applanation, and the
maximum deformation amplitude at the corneal apex.
4.2.3. Intraocular Pressure (IOP). POAG patients, both with
and without diabetes have also been studied using ORA. In a
study by Castro et al. [92], in which 74 eyes of 44 POAG
patients were evaluated, it was found that CH was signifi-
cantly higher in POAG patients with diabetes compared to
POAG individuals without diabetes, without finding dif-
ferences in the CCT. CRF, diabetes duration, and the effect
of metabolic control on corneal biomechanical properties
were not evaluated in this study. More recently, Akkaya et al.
[93], in a study of 101 eyes of 101 patients, found that CH in
diabetes was similar, but CRF, mean rim area, and rim
volume (measured by optical coherence tomography) were
found to be significantly higher in POAG patients with
diabetes when compared to POAG patients without diabetes
(Table 1). The results of these studies could suggest a pro-
tective role of diabetes in patients with glaucoma.
Several studies indicate a relationship between diabetes
and higher IOP values [78, 109, 112–114], but this association
is controversial. On one hand, diabetes is associated with a
thicker CCT, but a thick cornea also provides higher IOP
values. Luo et al. [120], in an extensive study, assessed both the
direct and indirect effect of diabetes on IOP through the CCT
mediator.They found that diabetes was associated with higher
IOP, and CCT only contributed in a small proportion to the
total effect of diabetes on IOP.This direct association between
diabetes and IOP may have a pathophysiological importance
with respect to the risk of glaucoma in people with diabetes.
4.2.4. Corneal Densitometry. Some studies on COD analysis
using the Pentacam HR imaging system in diabetes have
been recently published. COD is used to describe the
characteristics of the corneal tissue and makes it possible to
quantify its degree of transparency. Previous findings
showed that COD in an area of inflammation was higher
than normal, even when the damage was repaired [121]. It
has also been confirmed that Pentacam HR objectively as-
sesses a nubecula through a quantitative measurement of
corneal density [122]. Gao et al. [123] used Pentacam HRto
assess CCT, COD, and alterations of corneal transparency in
180 diabetes patients; they found an increase in COD and
CCT compared with controls, with a positive association
between the medial and intimal COD and central CCT in
diabetes patients. In addition, Calvo-Maroto et al. [124], in a
pilot study in adult diabetes patients, showed higher values
of corneal light backscatter in patients with diabetes when
compared with healthy subjects. However, COD values in
children with T1D were similar in all concentric zones and
layers to those in healthy children [125]. These findings
suggest that there is an influence of the age and/or time of
evolution of diabetes in the degree of corneal transparency
or COD as determined by Pentacam HR.
4.2.5. Analysis of Findings. The reason why diabetes is as-
sociated with increased CCT in cases without corneal epi-
theliopathy is still unknown. It has been speculated that
there may be an accumulation of AGEs in the corneal stroma
of patients with diabetes, along with a nonenzymatic cross-
linking between the collagen fibers and the proteoglycans.
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Table 1: Summary of prospective cross-sectional studies of CH, CRF, IOPg, and IOPcc in diabetes patients.
Author, year, country Study groups/sample size
Mean
age
(years)
ORA parameters (mean
mmHg) controls/diabetes
Outcomes
(P value) Associations
Goldich, 2008, Israel
[108]
40 with diabetes (40 eyes)/
40 controls (40 eyes) 60.9/63.8
CH: 10.7± 1.6/9.3± 1.4 0.0001 (i) Subjects with diabetes
had higher CH and CRF
values than those without
diabetes
CRF: 10.9± 1.7/9.6± 1.6 <0.0001
IOPcc: 16.6± 4.4/17.7± 4.9 0.31 (ii) There was no any
statistical difference
between the groups in terms
of IOPg and IOPcc.
IOPg: 16.6± 4.3/16.1± 4.9 0.66
Sahin, 2009, Turkey
[109]
43 with diabetes (81 eyes)/61
control (120 eyes) 55.3/53.1
CH: 9.51± 1.82/10.41± 1.66 0.0001 (i) CH was found to besignificantly lower in
diabetic patients
CRF: 10.32± 1.76/
10.36± 1.97 0.8 (ii)There was no significantdifference in terms of CRF
IOPcc: 18.81± 4.71/
15.85± 3.24 0.0001 (iii) Mean CCT, GAT,IOPg, and IOPcc were
significantly higher in
diabetic patients than in
healthy control subjects
IOPg: 17.68± 4.42/
15.34± 3.66 0.0001
Castro, 2010, Brazil [92]
44 primary open-angle
glaucoma patients)
CH: 9.1± 1.9/7.8± 1.7 0.04
Diabetic patients presented
significantly higher CH
values than patients without
diabetes. There was a
significant and positive
correlation between CH and
CCT for all patients
(r! 0.407, P< 0.001).
19 with diabetes (34 eyes)/
25 without diabetes (40 eyes
Kotecha, 2010, UK
[110]
61 with diabetes (61 eyes) 41.9/61.6/54.0
CH: 12.45± 1.74/
10.90± 1.94/10.85± 1.68
CRF: 12.49± 2.01/
11.50± 2.06/10.62± 1.64 0.008 (i) The CH wassignificantly greater in T1Dpatients.
T1D (13 eyes)/T2D (48
eyes)/controls (123 eyes) 0.0001
(ii) The CRF was
significantly greater in T1D
and T2D patients.
(iii) CH and CRF were
weakly correlated with
blood glucose concentration
Kara, 2012, Turkey [99] 46 T1D children (46 eyes)/50 controls (50 eyes) 14.2/14.5
CH: 12.3± 1.3/12.5± 1.5 0.609 (i) CH and CRF in T1D aresimilar to those of healthy
controls.
CRF: 12.4± 1.7/11.9± 1.5 0.152 (ii) IOPg and IOPcc in T1Dare similar to those of
healthy controls.
IOPg: 17.4± 3.6/16.7± 2.9 0.232
IOPcc: 15.5± 3.4/15.1± 2.7 0.446
Nalcacioglu-
Yuksekkaya, 2014,
Turkey [111]
68 T1D children (68 eyes)/
74 controls (74 eyes) 12.7/12.9
CH: 10.8± 1.5/10.7± 1.7 0.624 (i) CH and CRF in T1D aresimilar to those of healthy
controls.
CRF: 10.9± 1.9/10.5± 1.6 0.207 (ii) IOPg and IOPcc in T1Dare similar to those of
healthy controls.
IOPcc: 15.8± 3.0/15.3± 3.4 0.395
IOPg: 15.9± 3.7/15.2± 3.4 0.263
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Table 1: Continued.
Author, year, country Study groups/sample size
Mean
age
(years)
ORA parameters (mean
mmHg) controls/diabetes
Outcomes
(P value) Associations
Yazgan, 2014, Turkey
[112]
156 with T2D (156 eyes)/74
controls (74 eyes)
57.75/
57.91
CH: 10.37± 1.9/8.98± 1.4 0.0001
CH, CRF, CCT, IOPg and
IOPcc values were higher
in diabetes groups than
controls. There was also a
positive correlation between
HbA1C level and
intraocular pressure.
CRF: 11.06± 2.3/8.99± 1.5 0.0001
IOPg: 17.63± 3.9/14.80± 2.9 0.0001
IOPcc: 17.70± 3.2/
16.56± 2.4 0.026
Pe´rez-Rico, 2015, Spain
[113]
94 diabetic patients (94
eyes)
59.8/62.2
CH: 10.23± 1.83/
10.9± 1.39/11.43± 1.69 0.002
(i) CH was significantly
lower in diabetic patients
with elevated HbA1c than in
controls and was affected by
disease duration, whereas
the CRF remained
unaltered.
54 uncontrolled diabetes/40
controlled diabetes/41
controls
CRF: 11.05± 1.97/
11.21± 1.97/10.53± 1.78 0.263 (ii) IOPcc and IOPg weresignificantly higher indiabetic patients withelevated HbA1c than in
controls.
IOPcc: 18.45± 3.79/
14.68± 2.67/14.55± 3.72 <0.0001
IOPg: 18.16± 3.85/
15.31± 3.14/14.46± 4.1 <0.0001
Schweitzer, 2016,
France [91]
Diabetes (137 eyes)/controls
(695 eyes) —
CH: 9.79/9.28 0.003
Subjects with diabetes had
higher CH and CRF values
than those without diabetes.
Consistently, subjects
having fasting blood glucose
values greater than or equal
than 7.0mM had
significantly higher CH and
CRF mean values compared
with subjects having fasting
blood glucose values lower
than 6.1mM (P< 0.05).
CRF:10.35/9.63 0.003
Akkaya, 2016, Turkey
[93]
101 primary open-angle
glaucoma patients (101
eyes)
CH: 9.35 ± 1.49/8.86± 1.52 0.11 (i) CH in diabetes wassimilar to those of healthy
controls.
60 with diabetes (60 eyes)/41
without diabetes (41 eyes)
CRF: 10.15 ± 1.78/
9.24± 1.92 0.01 (ii) RNFL thickness wasmeasured by usingSpectralis HRA+OCT.
(iii) CRF, mean rim area,
and rim volume were found
to be significantly higher in
the diabetic group when
compared with nondiabetic
group.
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This cross-linking could theoretically explain the greater
rigidity and thickening of the cornea in diabetics (higher
CH, CRF, and CCT in some studies). Zou et al. [32]
compared eight monkeys with insulin-dependent diabetes
(induced by streptozotocin injection) with four controls, and
found a cross-linking with abnormal aggregates of collagen
fibrils in the stromal matrix on transmission electron mi-
croscope examination in monkeys with diabetes. In another
recent experimental study in rabbits, Bao et al. [126] in-
vestigated the effects of diabetes on the behavior of the
cornea, showing a significant increase in AGEs, CCT, and
IOP in rabbits with diabetes. In addition, the tangent
modulus of the cornea at four stress levels was significantly
higher in rabbits with diabetes, indicated by greater me-
chanical rigidity of the cornea.These findings are consistent
with evidence presented by Goldin et al. [127] in relation to
the AGE-induced cross-linking of the extracellular matrix of
certain tissues in patients with diabetes, which results in an
increase in arterial stiffness. The fact that children with
diabetes have the highest CCT without evidence of other
systemic complications of diabetes suggests that AGEs may
affect the cornea before other organs [95, 104] and that a test
as accessible as pachymetry may be used to detect early
changes.
The determination of corneal biomechanical properties
can provide information on changes in the extracellular
matrix in the eyes of diabetes patients and could therefore
offer a new parameter for monitoring the state of the disease.
In this review, we have found several studies conducted with
ORA that have investigated the influence of diabetes on the
biomechanical parameters of the cornea, but with somewhat
contradictory results. Most of them (Table 1) find higher CH
values in diabetes patients that could be caused by changes in
the fundamental substance of the cornea, which would
modify its viscosity [74, 108, 113, 115].The oxidative stress
caused by sustained hyperglycemia leads to the formation of
AGEs (by nonenzymatic glycosylation) that accumulate in
the tissues; in addition, a glycation of proteoglycans and
glycosaminoglycans of the matrix is proposed, which would
modify the viscosity of the cornea, increasing the CH [74,
115].
In addition, there are further pathogenic factors that
could modify the biomechanical properties of the cornea in
diabetes patients; these should be considered to clarify some
contradictory results in the published evidence. A dys-
function of the epithelial and endothelial cells of the cornea
could alter control of hydration of the cornea, causing
subclinical edema that could influence the results by causing
a decrease in CH and CRF, as well as an increase in CCT [74,
105, 126]. This hypothesis could explain the decreased CH
values reported in some studies [109, 113, 114] and the
elevated CCT in most of the studies [77–80]. Factors such as
axial length [128], possible endothelial dystrophy [105], the
existence of a subclinical keratoconus [129], or lubrication of
the surface [130] can produce significant biomechanical
changes that should be considered in future studies. In
addition, to determine how the parameters would change
during progression of the disease, measurement of the
biomechanical properties in the same patients over time
would be necessary. In future, we expect interesting findings
regarding the biomechanical properties of the cornea in
diabetes.
5. Diabetes and Endothelium
Table 2 summarizes the publications in the last ten years that
concern endothelial status in diabetes patients, compared in
most cases with healthy controls.
The italicized publications in Table 2 did not find sta-
tistically significant disagreement between the endothelial
cell density (ECD) of diabetes patients when compared with
healthy controls [72, 134, 135]. However, the majority of
authors found differences in the endothelial cell population
in individuals with versus without diabetes; the number of
cells is decreased in diabetes patients, especially in those with
T1D [12, 132, 133, 136]. Calvo-Maroto et al. [139] studied the
effect of diabetes duration and poor glycemic control on the
endothelial cell population: they found that the longer the
Table 1: Continued.
Author, year, country Study groups/sample size
Mean
age
(years)
ORA parameters (mean
mmHg) controls/diabetes
Outcomes
(P value) Associations
Bekmez, 2018, Turkey
[114]
50 with T2D (50 eyes)/50
controls (50 eyes) 63.3/61.7
CH: 9.9± 1.5/10.5± 1.7 0.080 (i) There was no any
statistical difference
between the groups in terms
of CH and CRF. However,
mean CH and CRF values
were found less in diabetic
group.
CRF: 10.4± 1.6/10.5± 1.7 0.730
IOPcc: 17.8± 3.6/16.0± 3.1 0.006 (ii) Corneal biomechanical
differences seen in diabetic
patients may be associated
with significantly higher
IOP measurements.
IOPg: 16.9± 3.5/15.4± 2.9 0.032
T1D! type 1 diabetes; T2D! type 2 diabetes; ORA! ocular response analyzer; CH! corneal hysteresis; CRF! corneal resistance factor; GAT!Goldmann
applanation tonometry; IOP! intraocular pressure; CCT!central corneal thickness; IOPg!Goldmann-correlated intraocular pressure; IOPcc! corneal-
compensated intraocular pressure.
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evolution time of diabetes, the greater the loss of endothelial
cells; this could be the reason why we find more differences
in T1D patients, who are generally of a younger age at disease
onset and usually present a longer duration of diabetes
evolution. Islam et al. [138], Anbar et al. [136], and Urban
et al. [133] also found this correlation between diabetes
duration and ECD.
According to Storr-Paulsen et al. [134], and although
they did not find statistically significant differences between
groups with respect to ECD, higher glycated hemoglobin
A1C levels were associated with lower ECD. Similar findings
were described by Mo´dis et al. [132] in T1D patients.
Therefore, we can conclude that patients with longer disease
evolution times and with poor metabolic control are those
with higher endothelial loss.
Regarding endothelial characteristics, diabetes patients
seem to have higher rates of polymegathism and lower
percentages of hexagonality (higher polymorphism) [79,
131, 136, 137]. Moreover, Anbar et al. [136] and Islam et al.
[138] found a significant correlation between the duration of
diabetes and pleomorphism and polymegathism, supporting
the idea that the longer the disease evolution, the more the
endothelial alteration.
Another indicator of endothelial cell dysfunction, along
with ECD, pleomorphism, and polymorphism, is CCT.The
healthy cornea stays in a state of dehydration, as endothelial
cell Na+/K+ ATPase and tight junctions are responsible for
limiting the entrance of aqueous humor into the stroma
[140]. When there is a substantial endothelial loss, the de-
crease in the number of tight junctions between cells allows
more fluid to enter the stroma, favoring stromal rehydration
with increased CCT that can lead to a loss of corneal
transparency. Several authors have reported higher CCT in
T1D [12, 133, 136] and T2D [77, 134] patients compared to
controls, and Calvo-Maroto et al. [139] reported higher CCT
in long-term T2D patients (diagnosed and treated for ten
years or more) when compared with short-term T2D pa-
tients and controls.
Endothelial changes in the diabetic cornea can alter their
function. Abnormal morphology of the corneal endothelial
cells combined with increased CCT is an indicator of al-
terations of endothelial pump function, which can lead the
cornea to a greater risk of decompensation following surgical
trauma. Thus, a complete endothelial examination is im-
portant before ophthalmological procedures such as cataract
surgery, since it is associated with an endothelial loss [141,
142].
5.1. InVitro Studies. In vitro studies carried out over the last
ten years with respect to the effect of diabetes on the corneal
endothelium are summarized in Table 3. The findings in
these donor tissue banks studies support the data observed
in in vivo studies. Chocron et al. [148] and Liaboe et al. [145]
reported lower levels of ECD in diabetes patients when
compared to controls. Chen et al. [147] described this en-
dothelial loss only in patients between 21 and 60 years;
subjects above this age did not have statistically significant
differences when compared to healthy controls. Moreover,
Kwon et al. [143] report that age, previous cataract surgery,
and diabetes were found to be the most important risk
factors for deficient donor quality with respect to ECD.
Schwarz et al. [144] designed a method to assess dif-
ferences in endothelium/Descemet membrane complex
adhesion strength from stroma between diabetic and non-
diabetic donor corneas. They did not find differences in
ECD, hexagonality, or coefficient of variation of cell area
between diabetes patients and controls; nevertheless, they
observed greater resistance in diabetes patients for the
separation between the endothelium/Descemet complex and
the stroma.
There are two publications that analyze mitochondrial
functioning in the endothelium of diabetes patients. Aldrich
et al. [146] report that endothelial cells from insulin-
dependent diabetes patients with medical complications
had variations in their mitochondrial configuration, notable
Golgi bodies associated with numerous vesicles, collection of
lysosomal bodies/autophagosomes, and focal production of
abnormal long-spacing collagen. Skeie et al. [149] found a
decrease in mitochondrial proteins in corneas taken from
patients with insulin-dependent diabetes when compared to
those from patients with non-insulin-dependent diabetes.
They suggest that proteins implicated in mitochondrial
dysfunction decrease to a greater extent as diabetes prog-
resses to insulin dependence, indicating that mitochondrial
changes may be linked to diabetes insulin therapy itself or
disease conditions at the time of transition to insulin
therapy.
6. New Therapeutic Perspectives
In the past decade, certain therapies to treat specific corneal
disorders in diabetes patients have been investigated. On one
hand, these patients can benefit from the available symp-
tomatic treatment options, such as artificial tear eye drops,
topical anti-inflammatory drugs [150] (NSAIDs, steroids,
and cyclosporine A), contact lenses [9], autologous serum,
or platelet-rich plasma [4, 151]. It is also known that a strict
metabolic control of blood glucose levels is important for
prevention and treatment of ocular surface alterations in
patients with diabetes [9]. On the other hand, new specific
therapies for diabetic keratopathy and neuropathy are being
investigated, even though they are in an experimental phase.
Local therapy with substance P and IGF-1 has been shown to
be effective in the treatment of diabetic keratopathy [152,
153], but more studies are needed to determine its effects on
other ocular structures before its use can be recommended.
There have also been studies that assess the effectiveness of
substances such as aldose reductase inhibitor [154], the anti-
inflammatory and healing agent TB4 [155], topical NGF
[156], resolvin D [157], oral nicergoline [158], and antiox-
idants such as carnosine and β-carotene [159]. However,
most of the suggested therapies have been investigated in
animal models. A promising agent that has shown efficacy in
several animal studies is naltrexone, an opioid antagonist
which blocks opioid-receptor binding, thereby accelerating
DNA synthesis [9]. In diabetes, there is an inhibition of cell
proliferation due to the production of excessive opioid
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Table 3: Summary of “in vitro” studies of the effect of diabetes on the corneal endothelium.
Author,
year Type of study Study groups Technology Parameters Results
Kwon,
2016 [143] Descriptive
18,665 donors (34,234
corneas)
Specular microscopy
(Konan Cell Chek EB-10;
Konan Medical, Hyogo,
Japan)
(i) Sex, age, race, surgery,
disease (hypertension,
diabetes, glaucoma,
depression, dementia,
Parkinson,
hyperthyroidism and
hypothyroidism) and
habits (smokers/
nonsmokers)
(ii) All independent
variables were divided
into 2 groups:
(1) ECD>2000 cels/mm2
(2) ECD<2000 cels/mm2
(i) ECD decreased with
age.
(ii) The average ECD of
African American donors
was higher than those of
white or Hispanic donors.
(iii) A history of diabetes
and ocular surgery were
associated with a lower
ECD.
(iv) Age, history of
cataract surgery and
diabetes were found to be
the greatest risk factors
for inadequate donor
quality with respect to
ECD.
Schwarz,
2016 [144] Case-control
22 donors (27 corneas):
(i) Nondiabetes (9 corneas,
8 donors)
(ii) Diabetes without
evidence of advanced
disease (8 corneas, 7
donors)
(iii) Diabetes with
evidence of advanced
disease (10 corneas, 7
donors).
(i) Specular microscopy
(technology not
specified)
(ii)The adhesion strength
of endothelium-descemet
membrane complex to
the posterior stroma was
measured by an own
method developed by the
investigators (see article).
(i) ECD, hexagonality,
and CV.
(ii) Variables obtained
from mechanical peel
testing were:
(1) Endothelium-
descemet membrane
complex elastic peel
tension (TE)
(2) Elastic stiffness (SE)
(3) Average delamination
tension (TD), and
maximum tension
(TMAX)
(i) The three groups did
not differ in ECD,
hexagonality, and CV.
(ii) Diabetes with
evidence of advanced
disease had values for TE,
TD, and TMAX greater
than nondiabetes and
diabetes without evidence
of advanced disease
corneas.
Liaboe,
2017 [145]
Retrospective
case-controls
2112 donors (4185
corneas) divided in 4
groups:
(i) Nondiabetes(2636
corneas)
(ii) NID-diabetes (847
corneas)
(iii) ID-diabetes without
medical complications due
to diabetes (471 corneas)
(iv) I-diabetes with
medical complications due
to diabetes (231 corneas).
Noncontact specular
microscopy
(KeratoAnalyzer EKA-10;
Konan Medical USA,
Irvine, CA)
Donor age, death to
preservation time, ECD,
hexagonality, and CV.
(i) I-diabetes with
medical complications
due to diabetes corneas
showed a significant
reduction in mean ECD
compared with
nondiabetic and NI-
diabetes.
(ii) There were no
significant differences in
endothelial cell
hexagonality or
coefficient of variation
among the 4 groups.
Journal of Ophthalmology 13
Table 3: Continued.
Author,
year Type of study Study groups Technology Parameters Results
Aldrich,
2017 [146] Case-control
159 donors (229 corneas)
all of them with ECD>
2000 cells/mm2. Divided
in 4 groups:
(i) Nondiabetes
(ii) NID-diabetes
(iii) ID-diabetes without
medical complications due
to diabetes
(iv) ID-diabetes with
medical complications due
to diabetes
(i) Noncontact specular
microscopy
(KeratoAnalyzer EKA-10;
Konan Medical USA,
Irvine, CA, USA)
(ii) Transmission electron
microscopes (EM 906E;
Carl Zeiss Microscopy,
Oberkochen, Germany)
(i) ECD, hexagonality,
and CV.
(ii) Qualitative and
quantitative
ultrastructural changes in
corneal endothelial cells
quantified with
transmission electron
microscope:
(iii) Number of
mitochondria per µm2,
surface area per
mitochondria in µm2, and
total mitochondrial
surface area per 20 µm2
field of view.
(i) ID-diabetes with
medical complications
due to diabetes displayed
the lowest spare
respiratory values
compared to all other
groups.
(ii) The remaining
mitochondrial
respiration and glycolysis
metrics did not differ
significantly among
groups.
(iii) Compared to
nondiabetes, the
endothelium from ID-
diabetes with medical
complications due to
diabetes had alterations
in mitochondrial
morphology, pronounced
Golgi bodies associated
with abundant vesicles,
accumulation of
lysosomal bodies/
autophagosomes, and
focal production of
abnormal long-spacing
collagen.
Chen,
2017 [147] Case-control
(i) 20,026 nondiabetes
donor eyes
(ii) 13,617 diabetes donor
eyes
Specular microscope
(Konan EB-10; Konan,
Hyogo, Japan).
ECD
Amongst phakic donors,
diabetic ECD was lower
in the middle aged
subgroups, between 21
and 40 years and between
41 and 60 years. There
was no difference in ECD
for phakic corneas from
the subset aged 61 years
or older.
Chocron,
2018 [148]
Retrospective
case-control
17056 donors:
(i) Diabetes (4766
patients):
(ii) Metformin consumers
(iii) Nonmetformin
consumers
(iv) Controls (12290
patients)
Specular microscopy
(Konan Cell Check EB-
10; Konan, Hyogo, Japan)
Age, sex, race, medical
history, medication list at
the time of death, and
ECD.
(i) ECD was lower in
patients with diabetes.
(ii) ECD was not
associated with
metformin use in patients
with diabetes.
(iii) Metformin use was
significantly associated
with lower ECD among
patients with glaucoma.
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growth factors.The topical application of naltrexone has been
shown to be useful both for corneal regeneration and tears
production, improving the corneal sensitivity in T1 and T2
diabetic animal models [45, 160]. In addition, there are
promising novel therapeutic approaches that include gene [23,
24, 41] and stem cells therapies [4, 44]; nevertheless, at the
moment, they are in preclinical development. In the near
future, we can expect some advances in the prevention and
management of corneal disorders associated with diabetes,
possibly from a multidisciplinary point of view.
In conclusion, different corneal components (epithe-
lium, stroma, nerves, and endothelium) suffer specific
complications of diabetes. The development of new non-
invasive diagnostic technologies has provided a better un-
derstanding of corneal tissue changes related to diabetes.The
published literature sheds light on the potential utility of the
biomechanical corneal properties to improve our un-
derstanding of the mechanical behavior of this complex
tissue in diabetes patients. However, the literature shows
controversial results in relevant areas such as CH and its
impact on IOPmeasurement. New technologies are showing
promise in consolidating the utility of the biomechanical
corneal properties as a clinical tool and a relevant field for
the future improvement of diagnosis of diabetes and control
of the disease.
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